Navigation Links
Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases

GOTHENBURG, Sweden, July 24, 2012 /PRNewswire/ --

Albireo AB (Gothenburg, Sweden; "Albireo"), a biopharmaceutical company specializing in gastroenterology, today announced that the European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on an application for orphan medicinal product status for the company's lead hepatology candidate, A4250, for the treatment of:

  • Primary Biliary Cirrhosis (PBC)
  • Progressive Familial Intrahepatic Cholestasis (PFIC)
  • Alagille Syndrome

The positive opinion of the COMP has now been forwarded to the EU commission for final approval. The designation would allow Albireo ten years of marketing exclusivity in EU member countries after obtaining market authorization, as well as streamlined regulatory review processes and registration.

"We are very pleased with the EMA´s recognition of our technology with A4250 as an orphan medicinal product for the treatment of these liver diseases in Europe", said Dr. Hans Graffner, Chief Medical officer at Albireo. "This designation is an important milestone in our efforts to provide a treatment for patients with cholestatic liver diseases; a disease entity often leading to severe symptoms, liver transplantation and with reduced survival. A4250 is an inhibitor of the bile acid transport mechanism and will decrease the toxic levels of bile acids in the liver cells."

About Primary Biliary Cirrhosis (PBC)

PBC is a slowly progressive autoimmune disease of the liver, primarily affecting women; average age when symptoms start is around 40-50 years of age. It is characterized by destruction of bile ducts resulting in an increased bile acid concentration in the liver inducing inflammation and cirrhosis. There are more than 100.000 patients with PBC in Europe. Main symptoms are fatigue, severe itching and symptoms of cirrhosis. There is no cure for PBC, some therapeutic alternatives may slow disease progression and relieve symptoms but some patients may need liver transplantation.

About Progressive Familial Intrahepatic Cholestasis (PFIC)

PFIC is a rare disease (estimated prevalence at birth 1/50.000 corresponding to more than 10.000 patients in the European Union) caused by a genetic defect impairing the transport of bile acids thereby inducing toxic levels of bile acid products in the liver inducing severe symptoms such as itching and scarring of the liver (cirrhosis) early in life. Although milder forms exist, most patients will develop symptoms in early childhood. Without any treatment, PFIC will lead to cirrhosis by age 10-20 years. In addition to supportive measures, the most common therapeutic modality is a surgical procedure thereby a portion of the bile production is either diverted to a stoma bag or by intestinal bypass to the large bowel. If the patient does not get better, or if there is evidence of liver cancer, then liver transplantation may be needed.

About Alagille Syndrome

Alagille syndrome is an inherited disease in which the patient has fewer than the normal number of bile ducts leading to increased concentration of bile acids in the liver which induce damage to the liver cells. The estimated number of patients with Alagille syndrome in the European Union is approximately 10.000-20.000. Jaundice, severe itching and growth problems are caused by the liver failure. Approximately 75% of the children diagnosed with Alagille syndrome live to 20 years of age; deaths most often caused by liver failure or heart complications.

About A4250

A4250 belongs to a class of inhibitors of the ileal bile acid transporter (IBAT, syn. apical sodium-dependent bile acid transporter ASBT). Usually bile excreted into the small bowel is being reused by a transport mechanism in which bile acids are absorbed in the distal part of the small bowel. A4250 decreases this re-absorption and will reduce the toxic levels of bile acids in the diseases described above. By using a specialized delivery technology, the bile acids will be neutralized in the large bowel.

About Albireo
Albireo AB is a Swedish biotechnology company focused on the development of novel therapeutic alternatives in the gastrointestinal area. In addition to A4250, Albireo has a pipeline of drug candidates for the development in areas such as IBD and functional gastrointestinal diseases. The lead program, elobixibat, is ready to enter Phase III in Chronic constipation and is also in development for IBS with constipation. Elobixibat is partnered with Ferring and with Ajinomoto. The Albireo management team has a broad experience in drug development, in particular in the GI area and has an extensive network in the international scientific and clinical communities. Albireo was created as a spin-out of AstraZeneca in 2008, financed by a syndicate of leading healthcare investors, led by Phase4 Ventures, and joined by TPG Biotech, TVM Capital and Scottish Widows Partnership.

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
2. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
3. Nephros Receives 510(k) Clearance for Hemodiafiltration System
4. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
5. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
6. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
7. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
8. Alexza Receives Complete Response Letter for Adasuve™ NDA
9. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
10. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
11. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
Post Your Comments:
(Date:11/24/2015)... York , 24. November 2015 /PRNewswire/ ... Avery Breathing Pacemaker Systems, ist erfreut, die ... Clinical Consultant bekannt geben zu können. ...   --> Foto - ... (Schweden). Von 1984-1986 war er ...
(Date:11/24/2015)... Nov. 24, 2015   HeartWare International, Inc . ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Chief Executive Officer Doug Godshall is scheduled ... Annual Healthcare Conference on December 1, 2015 at 3:00 ... in New York . ...
(Date:11/24/2015)... Mich. , Nov. 24, 2015 Diplomat Pharmacy, ... Senior Vice President of Clinical Services, Education and Human Resources ... online webinar, "Oral Oncology Drugs: Health Plan Strategies for a ... with Beckie Fenrick , a consultant with the Cambridge ... The webinar will discuss ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the nation’s leading provider ... pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic is designed to ... The location is scheduled to operate through Dec. 24. , Holiday Pop-Up Clinic , ...
(Date:11/24/2015)... ... November 24, 2015 , ... With Thanksgiving right around the ... safety tips to help protect your family and vehicle. , According to the National ... Thanksgiving holiday weekend. Amica is sharing the following safety tips from the NHTSA: ...
(Date:11/24/2015)... ... 2015 , ... Cold Shoulder , LLC launched their Pro Vest, the latest version of ... goal of $20,000 in under 10 hours. , The campaign, which will ... Loss Vest to the market. , The PRO Vest provides consumers with a less expensive, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... at Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, a ... and University President Carl S. Cleveland III on October 16. , “Katie is ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... exceptional customer service: the TrustDale certification. The award recognizes good companies for excellence ... honing , tile and grout, and hard surface restoration company earned this recognition ...
Breaking Medicine News(10 mins):